Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 8/20 | 0.67 |
| ▸ | COMT | P21964 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939184 | 1.00 | FTO (0.67) | FTOCOMTMEN1KMT2AABCC3 | |
| SCHEMBL4940519 | 0.95 | FTO (0.63) | FTOCOMTMEN1KMT2AABCC3 | |
| SCHEMBL4940512 | 0.95 | FTO (0.63) | FTOCOMTMEN1KMT2AABCC3 | |
| SCHEMBL4939116 | 0.95 | FTO (0.65) | FTOCOMTMEN1KMT2AABCC3 | |
| SCHEMBL4939120 | 0.95 | FTO (0.65) | FTOCOMTMEN1KMT2AABCC3 | |
| SCHEMBL4940726 | 0.94 | FTO (0.64) | FTOCOMTMEN1KMT2AABCC3 | |
| SCHEMBL4940731 | 0.94 | FTO (0.64) | FTOCOMTMEN1KMT2AABCC3 | |
| SCHEMBL4939534 | 0.93 | FTO (0.63) | FTOCOMTMEN1KMT2AABCC3 | |
| SCHEMBL5328263 | 0.93 | FTO (0.63) | FTOCOMTMEN1KMT2AABCC3 | |
| SCHEMBL4939529 | 0.93 | FTO (0.63) | FTOCOMTMEN1KMT2AABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103191-A1 | ENTACAPONE-DERIVATIVES | SCHWARZ PHARMA AG (DE) | 2008-05-01 | — | — | US | claimed |
| WO-2007144169-A2 | ENTACAPONE-DERIVATIVES | SCHWARZ PHARMA AG (DE) | 2007-12-21 | — | — | WO | claimed |
| US-20080103191-A1 | ENTACAPONE-DERIVATIVES | SCHWARZ PHARMA AG (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103191-A1 | ENTACAPONE-DERIVATIVES | SCHWARZ PHARMA AG (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103191-A1 | ENTACAPONE-DERIVATIVES | SCHWARZ PHARMA AG (DE) | 2008-05-01 | — | — | US | disclosed |
| WO-2007144169-A2 | ENTACAPONE-DERIVATIVES | SCHWARZ PHARMA AG (DE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144169-A2 | ENTACAPONE-DERIVATIVES | SCHWARZ PHARMA AG (DE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103191-A1 | ENTACAPONE-DERIVATIVES | ENTPD5, ENTPD3, ENTPD1 | FTO 2243/4885COMT 365/4885MEN1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.